학술논문
Outcomes of treatment of severe COVID-19 pneumonia with tocilizumab: a report of two cases from Tunisia.
Document Type
Article
Author
Source
Subject
*COVID-19 pandemic
*COVID-19 treatment
*COVID-19
*THERAPEUTICS
*TOCILIZUMAB
*THYROID crisis
*
*
*
*
*
Language
ISSN
1937-8688
Abstract
The SARS CoV-2 pandemic is a global health threat with high morbidity and mortality (1 to 4%) rates. COVID-19 is correlated with important immune disorders, including a "cytokine storm". A new therapeutic approach using the immunomodulatory drug, Anti-IL6 (tocilizimub), has been proposed to regulate it. We report here the first Tunisian experience using tocilizimub in two severe cases of COVID-19 pneumonia. The diagnosis was confirmed by chest scan tomography. Biological parameters showed a high level of Interleukin-6 (IL-6) that increased significantly during hospitalization. The patients developed hypoxia, so they received intravenously 8 mg/kg body weight tocilizumab. There was a resultant decrease in the level of IL6, with clinically good evolution. Blocking the cytokine IL-6 axis is a promising therapy for patients developing COVID-19 pathology. [ABSTRACT FROM AUTHOR]